A Comprehensive Analysis of Somatic Alterations in Chinese Ovarian Cancer Patients

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 12

PMID 33432021

Citations 10

Authors

Yingli Zhang

Xiaoliang Shi

Jiejie Zhang

Xi Chen

Peng Zhang

Angen Liu

Tao Zhu

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is one of the most common cancers in women and is often diagnosed as advanced stage because of the subtle symptoms of early ovarian cancer. To identify the somatic alterations and new biomarkers for the diagnosis and targeted therapy of Chinese ovarian cancer patients, a total of 65 Chinese ovarian cancer patients were enrolled for detection of genomic alterations. The most commonly mutated genes in ovarian cancers were TP53 (86.15%, 56/65), NF1 (13.85%, 9/65), NOTCH3 (10.77%, 7/65), and TERT (10.77%, 7/65). Statistical analysis showed that TP53 and LRP1B mutations were associated with the age of patients, KRAS, TP53, and PTEN mutations were significantly associated with tumor differentiation, and MED12, LRP2, PIK3R2, CCNE1, and LRP1B mutations were significantly associated with high tumor mutational burden. The mutation frequencies of LRP2 and NTRK3 in metastatic ovarian cancers were higher than those in primary tumors, but the difference was not significant (P = 0.072, for both). Molecular characteristics of three patients responding to olapanib supported that BRCA mutation and HRD related mutations is the target of olaparib in platinum sensitive patients. In conclusion we identified the somatic alterations and suggested a group of potential biomarkers for Chinese ovarian cancer patients. Our study provided a basis for further exploration of diagnosis and molecular targeted therapy for Chinese ovarian cancer patients.

Citing Articles

Putative Dual Roles of Bone Morphogenetic Protein 8B (BMP8B) in Disease Progression of Gastric Cancer.

Sun Z, Cai S, Liu X, Jiang W, Ye L Cancer Diagn Progn. 2024; 4(5):567-578.

PMID: 39238632 PMC: 11372696. DOI: 10.21873/cdp.10365.

An integrated machine learning-based model for joint diagnosis of ovarian cancer with multiple test indicators.

Feng Y J Ovarian Res. 2024; 17(1):45.

PMID: 38378582 PMC: 10877874. DOI: 10.1186/s13048-024-01365-9.

Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers.

Yi Z, Chen M, Sun S, Yang C, Mei Z, Yang H Cancer Innov. 2023; 1(3):220-228.

PMID: 38089758 PMC: 10686172. DOI: 10.1002/cai2.27.

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).

Pizarro D, Romero I, Perez-Mies B, Redondo A, Caniego-Casas T, Carretero-Barrio I Int J Mol Sci. 2023; 24(13).

PMID: 37446361 PMC: 10342764. DOI: 10.3390/ijms241311183.

Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience.

Kim Y, Chung Y, Lee J, Park E, Lee S, Kim S J Gynecol Oncol. 2023; 34(6):e70.

PMID: 37417298 PMC: 10627761. DOI: 10.3802/jgo.2023.34.e70.

References

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Jorge S, Swisher E, Norquist B, Pennington K, Gray H, Urban R . Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline mutations. Gynecol Oncol Rep. 2019; 29:113-117. PMC: 6710556. DOI: 10.1016/j.gore.2019.08.001. View

Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, Ruiz de Garibay G . Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One. 2015; 10(4):e0120020. PMC: 4382299. DOI: 10.1371/journal.pone.0120020. View

Monk B, Coleman R . Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer. 2009; 19 Suppl 2:S63-7. DOI: 10.1111/IGC.0b013e3181c104fa. View

Heeke A, Xiu J, Elliott A, Korn W, Lynce F, Pohlmann P . Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Res Treat. 2020; 184(2):265-275. DOI: 10.1007/s10549-020-05849-2. View

Garziera M, Cecchin E, Canzonieri V, Sorio R, Giorda G, Scalone S . Identification of Novel Somatic Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). Int J Mol Sci. 2018; 19(5). PMC: 5983728. DOI: 10.3390/ijms19051510. View

Freed-Pastor W, Prives C . Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-86. PMC: 3387655. DOI: 10.1101/gad.190678.112. View

Russell M, DAmato A, Graham C, Crosbie E, Gentry-Maharaj A, Ryan A . Novel risk models for early detection and screening of ovarian cancer. Oncotarget. 2016; 8(1):785-797. PMC: 5352196. DOI: 10.18632/oncotarget.13648. View

10.

Fortner R, Ose J, Merritt M, Schock H, Tjonneland A, Hansen L . Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. Int J Cancer. 2015; 137(5):1196-208. PMC: 6284794. DOI: 10.1002/ijc.29471. View

11.

Tian Y, Wang C, Chen S, Liu J, Fu Y, Luo Y . Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1. J Cell Sci. 2019; 132(15). DOI: 10.1242/jcs.228213. View

12.

Ashour M, Ezzat Shafik H . Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome. Cancer Manag Res. 2019; 11:6275-6284. PMC: 6626894. DOI: 10.2147/CMAR.S206817. View

13.

Wang M, Fan W, Ye M, Tian C, Zhao L, Wang J . Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. Sci Rep. 2018; 8(1):8990. PMC: 5997642. DOI: 10.1038/s41598-018-25583-6. View

14.

Grither W, Divine L, Meller E, Wilke D, Desai R, Loza A . TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis. Oncogene. 2018; 37(13):1714-1729. PMC: 5876071. DOI: 10.1038/s41388-017-0043-9. View

15.

Brachova P, Thiel K, Leslie K . The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci. 2013; 14(9):19257-75. PMC: 3794832. DOI: 10.3390/ijms140919257. View

16.

Morse C, Elvin J, Gay L, Liao J . Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecol Oncol Rep. 2017; 21:78-80. PMC: 5510487. DOI: 10.1016/j.gore.2017.06.013. View

17.

Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K . KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 2008; 99(12):2020-8. PMC: 2607229. DOI: 10.1038/sj.bjc.6604783. View

18.

Shen W, Li H, Liu L, Cheng J . Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer. Eur Rev Med Pharmacol Sci. 2017; 21(11):2596-2603. View

19.

Brachova P, Mueting S, Carlson M, Goodheart M, Button A, Mott S . TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 2014; 46(2):607-18. PMC: 4277253. DOI: 10.3892/ijo.2014.2747. View

20.

Balendran S, Liebmann-Reindl S, Berghoff A, Reischer T, Popitsch N, Geier C . Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations. J Neurooncol. 2017; 133(3):469-476. PMC: 5537326. DOI: 10.1007/s11060-017-2459-z. View